Lv4
660 积分 2024-10-29 加入
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
9天前
已完结
Telitacicept: First Approval
9天前
已完结
Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease
11天前
已完结
Daratumumab for multidrug-resistant phospholipase-A2 receptor–related membranous nephropathy
18天前
已完结
Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up
18天前
已完结
Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series
18天前
已完结
ANCA-associated vasculitis
1个月前
已完结
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
1个月前
已完结
Efficacy of Long-Term Repeated Rituximab Treatment in Refractory Phospholipase A2 Receptor-Antibody-Related Membranous Nephropathy
1个月前
已完结
Urinary rituximab loss and rate of treatment failure in membranous nephropathy
1个月前
已完结
皖公网安备34019202002308
